63 Biggest Movers From Yesterday
Gainers
Support.com, Inc. (NASDAQ: SPRT) shares surged 41.1% to settle at $19.70 on Thursday on abnormally high volume.
Mid-Afternoon Market Update: Pure Storage Rises Following Strong Q2 Results; SelectQuote Shares Plunge
Toward the end of trading Thursday, the Dow traded down 0.38% to 35,270.96 while the NASDAQ fell 0.35% to 14,988.64. The S&P also fell, dropping 0.40% to 4,483.22.
What 8 Analyst Ratings Have To Say About Ascendis Pharma
Ascendis Pharma (NASDAQ:ASND) has observed the following analyst ratings within the last quarter:
Bullish
Somewhat Bullish
Indifferent
Mid-Day Market Update: Dow Tumbles Over 100 Points; Ascendis Pharma Shares Spike Higher
Midway through trading Thursday, the Dow traded down 0.33% to 35,288.79 while the NASDAQ fell 0.62% to 14,948.24. The S&P also fell, dropping 0.53% to 4,472.56.
45 Stocks Moving In Thursday’s Mid-Day Session
Gainers
Blue Water Acquisition Corp. (NASDAQ: BLUW) shares climbed 57% to $16.41. Blue Water Acquisition is expected to hold a special meeting of its stockholders on Friday, August 27, 2021.
See Why Ascendis Pharma Stock Is Shining On Thursday
The FDA on Wednesday gave a thumbs-up to Ascendis Pharma A/S's (NASD
Mid-Morning Market Update: Markets Mixed; Dollar General Profit Beats Views
Following the market opening Thursday, the Dow traded up 0.15% to 35,458.00 while the NASDAQ rose 0.02% to 15,044.79. The S&P, however, dropped 0.12% to 4,490.91.
Recap: Ascendis Pharma Q2 Earnings
Shares of Ascendis Pharma (NASDAQ:ASND) rose 23.2% in after-market trading after the company reported Q2 results.
Quarterly Results
Earnings per share decreased 38.71% year over year to ($3.01), which missed the estimate of ($2.75).
Morgan Stanley Maintains Overweight on Ascendis Pharma, Raises Price Target to $204
Morgan Stanley maintains Ascendis Pharma (NASDAQ:ASND) with a Overweight and raises the price target from $197 to $204.
The Daily Biotech Pulse: Early Approval For Ascendis’ Pediatric Growth Hormone Deficiency Treatment, Redhill Biopharma Spikes On Positive COVID-19 Drug Data, RenovoRx IPO
Here's a roundup of top developments in the biotech space over the last 24 hours:
Scaling The Peaks
(Biotech Stocks Hitting 52-week Highs Aug. 25)